Genmab A (GMAB) Payables (2025 - 2026)
Genmab A (GMAB) reported Payables of $275.0 million for Q1 2026, up 0.73% quarter-over-quarter from $273.0 million in Q4 2025.
Genmab A (GMAB) Payables (2025 - 2026) Analysis & Trends
Genmab A has reported Payables for 2 years, with the latest figure at $275.0 million in Q1 2026.
- For the quarter ending Q1 2026, Payables changed N/A year-over-year to $275.0 million; the trailing twelve-month figure through Mar 2026 stood at $275.0 million (changed N/A YoY), and the FY2025 full-year result was $273.0 million, changed N/A from the prior year.
- Payables for Q1 2026 stood at $275.0 million, up from $273.0 million in the prior quarter.
- The five-year high for Payables was $275.0 million in Q1 2026, with the low at $273.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 300,549.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.69 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Genmab A | 48.57 Bn | 47.05 Bn | 831.00 Mn | 275.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.00 Mn |
| Dec 31, 2025 | 273.00 Mn |